QCIF is proud to support Queensland’s biomedical research community through a statewide shared license for QIAGEN Ingenuity Pathway Analysis (IPA), a powerful bioinformatics tool that enables researchers to interpret complex omics data by mapping it to known biological pathways and networks.
Through this license, researchers will gain access to IPA’s proprietary Knowledge Base, a repository of expertly curated biological interactions and functional annotations created from peer-reviewed literature. This resource provides high quality, biologically insights that go beyond raw data found in public databases.
IPA also supports access to its Knowledge Base through an intuitive, user-friendly interactive interface with functionalities like upstream regulator prediction and causal network modelling, enabling researchers to explore and understand the biological relevance of their findings more effectively.
With this capabilities, IPA supports the discovery of molecular mechanisms, identification of biomarkers, and prediction of downstream effects, ultimately accelerating scientific discovery across health and life sciences.
Flexible access to IPA through QCIF's shared licence model
Since for some researchers, bioinformatics tools like IPA are used most intensively during specific stages of the research cycle, QCIF has partnered with QIAGEN to offer a flexible shared licence model.
This initiative provides researchers across multiple institutions in Queensland with timely access to IPA when it's needed most, without the financial burden of full-time licencing.
The shared licence supports two concurrent users and ensures equitable access through a streamlined registration process and a managed booking system, making advanced bioinformatics more accessible and collaborative.
"Access to IPA and the associated support through QCIF has enabled a newfound capacity in our team to generate insightful bioinformatics analyses from our proteomics datasets. Previously, we were entirely reliant on collaborators or other, less effective software packages that were not accessible or intuitive. Such difficulties prove to be major obstacles for new entrants to this kind of analysis; this is resolved with access to IPA which represents an easy-to-use, powerful software.
I am eager to continue using IPA to generate bioinformatics analyses for informing future hypotheses and contributing to impactful research and consequent publications within our team."
— Anuk Indraratna, Institute for Biomedicine and Glycomics, Griffith University
Usage highlights
Since launching the shared license in August 2023:
211 registered users have completed 2,397 sessions
This represents a total of 3,228 hours of IPA usage
QCIF is proud to continue its collaboration with QIAGEN, reinforcing our shared commitment to empowering researchers with cutting-edge digital research infrastructure.
This initiative exemplifies our dedication to breaking down barriers by providing equitable, cost-effective access to high-value tools like IPA.
"We're glad to have partnered with QCIF to enable academic researchers across Queensland to harness the unique insights from IPA and IPA Interpret at an affordable cost. QCIF has also been instrumental in providing training to get users up to speed quickly."
— Stuart Tugendreich, PhD, Director and Global Product Manager of IPA
Get started with IPA
Staff and students from participating Queensland universities can register to access QIAGEN Ingenuity Pathway Analysis (IPA) via QCIF via our request form.